MTOR and breast cancer: The inhibition of this pathway by specific PI3K and mTOR inhibitors (LY294002 and rapamycin, respectively) led to a reduction of cell survival and tumorigenicity of the putative breast cancer stem MCF-7 cell population, defined by the side population assay [17].